MX384378B - Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca. - Google Patents

Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.

Info

Publication number
MX384378B
MX384378B MX2015001826A MX2015001826A MX384378B MX 384378 B MX384378 B MX 384378B MX 2015001826 A MX2015001826 A MX 2015001826A MX 2015001826 A MX2015001826 A MX 2015001826A MX 384378 B MX384378 B MX 384378B
Authority
MX
Mexico
Prior art keywords
treatment
heart failure
subsecence
neuroregulin
prophylaxis
Prior art date
Application number
MX2015001826A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Caggiano
Anindita Ganguly
Jennifer Iaci
Tom Parry
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MX384378B publication Critical patent/MX384378B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015001826A 2008-07-17 2009-07-17 Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca. MX384378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
PCT/US2009/004130 WO2010030317A2 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
MX384378B true MX384378B (es) 2025-03-14

Family

ID=42005671

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015001826A MX384378B (es) 2008-07-17 2009-07-17 Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
MX2011000696A MX2011000696A (es) 2008-07-17 2009-07-17 Dosificacion terapeutica de una neurregulina o una subsecuencia de la misma para el tratamiento o la profilaxis de insuficiencia cardiaca.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000696A MX2011000696A (es) 2008-07-17 2009-07-17 Dosificacion terapeutica de una neurregulina o una subsecuencia de la misma para el tratamiento o la profilaxis de insuficiencia cardiaca.

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP3338791B1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN104623633A (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK2320933T3 (enExample)
ES (2) ES2664394T3 (enExample)
MX (2) MX384378B (enExample)
PL (2) PL3338791T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013149163A1 (en) * 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3353546A1 (en) 2015-09-25 2018-08-01 Douglas B. Sawyer Methods for treating cardiac injury
US11426447B2 (en) * 2016-04-19 2022-08-30 Leibniz-Institut Fur Alternsforschung—Fritz-Lipmann-Institut E.V. (Fli) Neuregulin for the treatment of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US12649769B2 (en) 2019-09-16 2026-06-09 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
WO2001034174A2 (en) 1999-11-12 2001-05-17 Entremed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP2005525317A (ja) 2002-01-18 2005-08-25 カイロン コーポレイション Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20070010518A1 (en) * 2005-02-18 2007-01-11 Matti Kivikko Method for administering levosimendan
MX2007010603A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
CN102026651B (zh) 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
WO2013149163A1 (en) 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury

Also Published As

Publication number Publication date
EP3338791B1 (en) 2019-09-18
RU2536938C2 (ru) 2014-12-27
AU2017203528A1 (en) 2017-06-15
CN107019794B (zh) 2021-03-12
ES2763184T3 (es) 2020-05-27
US20110166068A1 (en) 2011-07-07
US20200009228A1 (en) 2020-01-09
JP2011528353A (ja) 2011-11-17
EP2320933A1 (en) 2011-05-18
WO2010030317A2 (en) 2010-03-18
JP6189879B2 (ja) 2017-08-30
JP2015129137A (ja) 2015-07-16
US20160113999A1 (en) 2016-04-28
CA2731113A1 (en) 2010-03-18
CN102159236A (zh) 2011-08-17
JP5797112B2 (ja) 2015-10-21
PL3338791T3 (pl) 2020-04-30
JP2019196370A (ja) 2019-11-14
AU2009292216B2 (en) 2015-03-05
AU2009292216A1 (en) 2010-03-18
RU2020111236A3 (enExample) 2021-09-21
CN107019794A (zh) 2017-08-08
DK2320933T3 (en) 2018-04-16
RU2719199C1 (ru) 2020-04-17
PL2320933T3 (pl) 2018-07-31
EP2320933A4 (en) 2013-02-27
BRPI0916442A2 (pt) 2018-06-19
AU2015202877A1 (en) 2015-06-18
RU2020111236A (ru) 2021-09-21
RU2011105821A (ru) 2012-08-27
EP3632459A1 (en) 2020-04-08
US9198951B2 (en) 2015-12-01
JP2022023208A (ja) 2022-02-07
US11235031B2 (en) 2022-02-01
ES2664394T3 (es) 2018-04-19
EP2320933B1 (en) 2017-12-27
EP3338791A1 (en) 2018-06-27
US20130324466A1 (en) 2013-12-05
US20180280477A1 (en) 2018-10-04
RU2698090C2 (ru) 2019-08-22
RU2014141514A (ru) 2016-05-10
MX2011000696A (es) 2011-07-29
AU2015202877B2 (en) 2017-03-09
JP2017200949A (ja) 2017-11-09
HK1256637A1 (en) 2019-09-27
US9956266B2 (en) 2018-05-01
CN104623633A (zh) 2015-05-20
DK3338791T3 (da) 2019-12-16

Similar Documents

Publication Publication Date Title
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
CO6382125A2 (es) Inhibidores de proteína quinasa
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201490254A1 (ru) Комбинированное лечение гепатита с
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
MX350046B (es) Tratamientos para trastornos gastrointestinales.
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
CR20170320A (es) Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ECSP077340A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA201500061A1 (ru) Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
NZ700467A (en) Treatments suitable for malassezia infections
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
CO2020001742A2 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil
MX380927B (es) Promotor de absorcion gi superior amortiguado.
BR112015013223A2 (pt) composição farmacêutica